Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home
197 items matching your search terms.
Filter the results.
Item type














New items since



Sort by relevance · date (newest first) · alphabetically
UNC Bone Marrow and Stem Cell Transplantation Program achieves outstanding outcomes
by Mary Ruth published May 10, 2012 last modified May 10, 2012 02:08 PM — filed under: ,
Chapel Hill, NC –A medical procedure called allogeneic hematopoietic cell transplantation, commonly known as a bone marrow or stem cell transplant, is the only known curative option for many patients with life-threatening blood-borne cancers such as leukemia and lymphoma.
Located in News / 2012 News
Molecular subtypes and genetic alterations may determine response to lung cancer therapy
by Mary Ruth published May 11, 2012 last modified May 23, 2012 10:22 AM — filed under: , ,
Chapel Hill - Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient’s individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient’s response to therapy.
Located in News / 2012 News
Study shows benefit of new maintenance therapy for multiple myeloma
by Mary Ruth published May 11, 2012 last modified May 14, 2012 12:56 PM — filed under: , ,
Chapel Hill, NC – Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.
Located in News / 2012 News
DNA replication protein also has a role in mitosis, cancer
by Mary Ruth published May 14, 2012 last modified May 14, 2012 02:21 PM — filed under: ,
The finding presents a possible explanation for why so many cancers possess not just genomic instability, but also more or less than the usual 46 DNA-containing chromosomes.
Located in News / 2012 News
Grant to fund use of kinase test in HER2-positive breast cancer
by Mary Ruth published May 14, 2012 last modified May 15, 2012 03:49 PM — filed under: , ,
Chapel Hill, NC – Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer.
Located in News / 2012 News
HHMI Bulletin explores James Bear's research
by Mary Ruth published May 16, 2012 last modified May 16, 2012 09:54 AM — filed under: , ,
Located in News / 2012 News
Berg quoted in The Wall Street Journal's Health Blog
by Mary Ruth published May 16, 2012 last modified May 16, 2012 12:25 PM — filed under: ,
Located in News / 2012 News
Norman E. Sharpless, MD, appointed the Wellcome Distinguished Professor in Cancer Research
by Mary Ruth published May 15, 2012 last modified May 23, 2012 08:48 AM — filed under: , ,
Chapel Hill, NC – Norman E. “Ned” Sharpless, MD, professor of medicine and genetics and Associate Director for Translational Research at UNC Lineberger Comprehensive Cancer Center has been appointed the Wellcome Distinguished Professor in Cancer Research. The professorship was established by the School of Medicine in 1988 with gifts from the Burroughs Wellcome Fund and the William A. Smith Trust of Wadesboro, NC. The gifts were supplemented by the state of North Carolina the Distinguished Professors Endowment Trust Fund to create the endowed professorship.
Located in News / 2012 News
UNC study highlights diagnosis of lung cancer subtypes
by Mary Ruth published May 17, 2012 last modified May 17, 2012 09:24 AM — filed under: , ,
In the processes of treating most cancers, one of the key pieces of information is the appearance of the tumor under the microscope using a technique called light microscopy. In lung cancer, for example, the appearance of the tumor determines both which chemotherapies are safe and which chemotherapies are effective. In addition, tumor appearance also suggests which patients should be tested for mutations that can be targeted by some of the most effective and safest drugs on the market.
Located in News / 2012 News
Bae-Jump to serve on NCI's Gynecologic Cancer Steering Committee
by Mary Ruth published May 17, 2012 last modified May 17, 2012 03:25 PM — filed under: ,
Victoria Bae-Jump, MD, PhD will serve a two-year term as a junior investigator on the Gynecologic Cancer Steering Committee of the National Cancer Institute, a member institute of the National Institutes of Health.
Located in News / 2012 News